MX375442B - Un agente terapéutico y un agente mejorador de la permeación intracelular para usarse en el tratamiento de cáncer. - Google Patents

Un agente terapéutico y un agente mejorador de la permeación intracelular para usarse en el tratamiento de cáncer.

Info

Publication number
MX375442B
MX375442B MX2015003643A MX2015003643A MX375442B MX 375442 B MX375442 B MX 375442B MX 2015003643 A MX2015003643 A MX 2015003643A MX 2015003643 A MX2015003643 A MX 2015003643A MX 375442 B MX375442 B MX 375442B
Authority
MX
Mexico
Prior art keywords
treating cancer
agent
provides
penetration enhancing
intracellular penetration
Prior art date
Application number
MX2015003643A
Other languages
English (en)
Other versions
MX2015003643A (es
Inventor
Lewis Bender
Original Assignee
Intensity Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50341876&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX375442(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intensity Therapeutics Inc filed Critical Intensity Therapeutics Inc
Publication of MX2015003643A publication Critical patent/MX2015003643A/es
Publication of MX375442B publication Critical patent/MX375442B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/042—Gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/20—Halogens; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/342—Alcohols having more than seven atoms in an unbroken chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/345—Alcohols containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A61K8/416—Quaternary ammonium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/12—Preparations containing hair conditioners
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/30—Characterized by the absence of a particular group of ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/30—Characterized by the absence of a particular group of ingredients
    • A61K2800/34—Free of silicones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/524—Preservatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)

Abstract

La invención proporciona un método para tratar el cáncer que usa una estrategia de coadministración que combina la coadministración local de un agente terapéutico y un agente mejorador de la penetración intracelular, y opcionalmente en combinación con la administración local de un agente inmunoterapéutico, como una vacuna contra cáncer o un agonista de NKT. La invención también proporciona un método para tratar el cáncer que usa un agente mejorador de la penetración intracelular. Los métodos de la invención buscan matar y/o destruir sustancialmente las células tumorales objetivo, así como aquellas células cancerosas que han hecho metástasis en otras partes del cuerpo.
MX2015003643A 2012-09-21 2013-09-15 Un agente terapéutico y un agente mejorador de la permeación intracelular para usarse en el tratamiento de cáncer. MX375442B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261703890P 2012-09-21 2012-09-21
US201261707733P 2012-09-28 2012-09-28
US201361779509P 2013-03-13 2013-03-13
PCT/US2013/059841 WO2014046983A1 (en) 2012-09-21 2013-09-15 Method of treating cancer

Publications (2)

Publication Number Publication Date
MX2015003643A MX2015003643A (es) 2016-04-06
MX375442B true MX375442B (es) 2025-03-06

Family

ID=50341876

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015003643A MX375442B (es) 2012-09-21 2013-09-15 Un agente terapéutico y un agente mejorador de la permeación intracelular para usarse en el tratamiento de cáncer.

Country Status (20)

Country Link
US (6) US9351997B2 (es)
EP (1) EP2897620B1 (es)
JP (2) JP6374388B2 (es)
KR (1) KR101839864B1 (es)
CN (1) CN104884065B (es)
AU (2) AU2013318338B2 (es)
BR (1) BR112015006176B1 (es)
CA (1) CA2884707C (es)
CL (1) CL2015000699A1 (es)
CY (1) CY1123258T1 (es)
DK (1) DK2897620T3 (es)
ES (1) ES2813340T3 (es)
IL (1) IL237791B (es)
MX (1) MX375442B (es)
PL (1) PL2897620T3 (es)
PT (1) PT2897620T (es)
RU (1) RU2657749C2 (es)
SG (2) SG11201501850VA (es)
SM (1) SMT202000452T1 (es)
WO (1) WO2014046983A1 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2897620T (pt) 2012-09-21 2020-09-03 Intensity Therapeutics Inc Método de tratamento de cancro
US10252945B2 (en) 2012-09-26 2019-04-09 Multiple Energy Technologies Llc Bioceramic compositions
BR112015009134A2 (pt) * 2012-10-25 2017-07-04 Glaxosmithkline Llc combinação
WO2014193898A1 (en) * 2013-05-31 2014-12-04 Merck Sharp & Dohme Corp. Combination therapies for cancer
TWI539960B (zh) 2013-06-21 2016-07-01 凱爾傑姆維克斯有限公司 激素分泌調節劑、包括其的組成物以及其用途
HUE046249T2 (hu) 2013-12-12 2020-02-28 Shanghai hengrui pharmaceutical co ltd PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása
ES2809251T3 (es) 2013-12-17 2021-03-03 Gemvax & Kael Co Ltd Composición para tratar cáncer de próstata
WO2016062285A1 (zh) * 2014-10-24 2016-04-28 朗齐生物医学股份有限公司 神经系统疾病用药在制备抗癌医药组合物中的应用
US20160166679A1 (en) * 2014-12-12 2016-06-16 Purdue Research Foundation Method of treatment using folate conjugates and tyrosine kinase inhibitors
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
CN105983097B (zh) * 2015-01-28 2021-06-08 华中科技大学同济医学院附属协和医院 一种抗肿瘤制剂及其制备方法
EP3263122B1 (en) * 2015-02-27 2020-05-06 Gemvax & Kael Co., Ltd. Peptide for preventing hearing loss, and composition comprising same
EP3267969A1 (en) * 2015-03-09 2018-01-17 King's College London Combination therapy with rar alpha agonists for enhancing th1 response
WO2016146143A1 (en) 2015-03-16 2016-09-22 Amal Therapeutics Sa Cell penetrating peptides and complexes comprising the same
US10722527B2 (en) 2015-04-10 2020-07-28 Capsugel Belgium Nv Abiraterone acetate lipid formulations
JP6921759B2 (ja) 2015-06-04 2021-08-18 クリティテック・インコーポレイテッド 捕集装置および使用法
ES2760699T3 (es) * 2015-06-18 2020-05-14 Vaximm Ag Vacuna de ADN dirigida al VEGFR-2 para terapia de combinación
WO2017003267A1 (ko) 2015-07-02 2017-01-05 주식회사 젬백스앤카엘 항바이러스 활성 효능을 가지는 펩티드 및 이를 포함하는 조성물
CA2991455C (en) * 2015-07-24 2023-10-10 Kimberly-Clark Worldwide, Inc. Methods for better delivery of active agents to tumors
CN105241872B (zh) * 2015-09-01 2018-09-25 中国科学院深圳先进技术研究院 检测血液中半乳凝集素-1的方法及所用试剂
KR20180093990A (ko) * 2015-12-07 2018-08-22 고쿠리츠 다이가쿠 호진 교토 다이가쿠 Pd-1 시그널 저해제의 병용 요법
TWI733719B (zh) 2015-12-07 2021-07-21 美商河谷控股Ｉｐ有限責任公司 改善的組合物及用於新表位之病毒遞送的方法及其應用
EP3419668B1 (en) * 2016-02-24 2025-06-04 Ramot at Tel-Aviv University Ltd. Polymeric conjugates and uses thereof
PT3429618T (pt) 2016-03-16 2024-04-02 Amal Therapeutics Sa Combinação de um modulador de ponto de controlo imunitário e um complexo que compreende um péptido de penetração celular, uma carga e um agonistra peptídico de tlr para utilização em medicina
SG10201913409VA (en) 2016-04-04 2020-03-30 Crititech Inc Methods for solid tumor treatment
WO2017176087A1 (ko) 2016-04-07 2017-10-12 주식회사 젬백스앤카엘 텔로머라제 활성 증가 및 텔로미어 연장 효능을 가지는 펩티드 및 이를 포함하는 조성물
US10588974B2 (en) 2016-04-22 2020-03-17 Receptor Holdings, Inc. Fast-acting plant-based medicinal compounds and nutritional supplements
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
US20190183798A1 (en) * 2016-06-17 2019-06-20 Johnpro Biotech Inc. Method for treating tumor
WO2018050782A1 (en) * 2016-09-14 2018-03-22 Abivax Combinations including abx196 for the treatment of cancer
IL265479B (en) 2016-09-21 2022-09-01 Amal Therapeutics Sa A fusion containing a cell-penetrating peptide, a multiple epitope, and a peptide tlr agonist for cancer therapy
EA201892396A1 (ru) * 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
CN115919815A (zh) 2017-06-14 2023-04-07 克里蒂泰克公司 治疗肺部疾病的方法
WO2019042247A1 (zh) * 2017-08-28 2019-03-07 江苏恒瑞医药股份有限公司 一种cyp17抑制剂的药物组合物及其制备方法
CN107475181B (zh) 2017-09-30 2021-03-02 中国农业大学 未成熟卵母细胞的体外成熟培养液及其应用
KR20200064112A (ko) 2017-10-03 2020-06-05 크리티테크, 인크. 암의 치료를 위한 면역치료제의 전신 전달과 조합된 항신생물성 입자의 국소 전달
EA202090889A1 (ru) * 2017-10-05 2020-08-19 Ресептор Холдингз, Инк. Травяные композиции с улучшенной биодоступностью
BR112020006841A2 (pt) * 2017-10-05 2020-10-06 Receptor Holdings, Inc. formulações de canabinoide sintéticas e à base de planta com ação prolongada e início rápido
BR112021003477A2 (pt) * 2018-06-14 2021-05-18 Metabolomycs, Inc. assinaturas metabolômicas para prever, diagnosticar e prognosticar várias doenças incluindo câncer
RU2704020C1 (ru) * 2018-06-22 2019-10-23 Общество с ограниченной ответственностью "ПеритонТрит" Комбинация дегидроксиметилэпоксихиномицина (DHMEQ) и цитостатиков для лечения рака яичника
WO2020081148A1 (en) 2018-10-16 2020-04-23 US Nano Food & Drug INC Intratumor injection formulation
UY38480A (es) 2018-11-19 2020-06-30 Receptor Holdings Inc Aminoácidos grasos n-acilados para reducir la variabilidad de absorción en composiciones a base de cannabinoides
EP4005583A4 (en) * 2019-04-01 2023-04-26 Industry - University Cooperation Foundation Hanyang University ANTI-CANCER AGAINST PEPTIDE-BASED CP2C
WO2021124272A1 (en) * 2019-12-19 2021-06-24 Liminal Biosciences Limited Cycloalkyl-containing carboxylic acids and uses thereof
CN114929213A (zh) 2020-04-13 2022-08-19 美国纳米食品药品公司 碱性化疗药瘤内注射剂组合物
CR20230308A (es) * 2020-12-11 2023-09-08 Civi Biopharma Inc Entrega oral de conjugados antisentido que tienen por blanco a pcsk9
WO2022197743A1 (en) * 2021-03-16 2022-09-22 Multiple Energy Technologies Llc Bioceramic compositions for cancer recovery
US11541134B1 (en) 2021-08-02 2023-01-03 Rayzebio, Inc. Stabilized compositions of radionuclides and uses thereof
CN121263449A (zh) 2023-03-21 2026-01-02 拜格拉夫55公司 Cd19/cd38多特异性抗体

Family Cites Families (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4619913A (en) 1984-05-29 1986-10-28 Matrix Pharmaceuticals, Inc. Treatments employing drug-containing matrices for introduction into cellular lesion areas
USRE35748E (en) * 1984-05-29 1998-03-17 Matrix Pharmaceutical, Inc. Treatments employing drug containing matrices for introduction into cellular lesion areas
US4764381A (en) 1985-12-06 1988-08-16 Key Pharmaceuticals, Inc. Percutaneous penetration enhancer of oleic acid and 2-ethyl-1, 3-hexanediol
US4983396A (en) 1985-12-06 1991-01-08 Key Pharmaceuticals, Inc. Percutaneous penetration enhancer of oleic acid and 2-ethyl-1,3-hexanediol
USRE35862E (en) 1986-08-18 1998-07-28 Emisphere Technologies, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
US5118845A (en) 1986-09-29 1992-06-02 Whitby Research, Inc. Penetration enhancer for transdermal delivery of systemic agents
US4783450A (en) 1987-04-13 1988-11-08 Warner-Lambert Company Use of commercial lecithin as skin penetration enhancer
US5045553A (en) 1987-06-24 1991-09-03 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter
US4978332A (en) * 1987-09-28 1990-12-18 Matrix Pharmaceutical, Inc. Treatments employing vasoconstrictive substances in combination with cytotoxic agents for introduction into cellular lesion areas
US5162115A (en) * 1989-05-09 1992-11-10 Pietronigro Dennis D Antineoplastic solution and method for treating neoplasms
US5219877A (en) 1989-09-25 1993-06-15 Bristol-Myers Squibb Company Lauryl alcohol as skin penetration enhancer for topical imidazole agents
US5451410A (en) 1993-04-22 1995-09-19 Emisphere Technologies, Inc. Modified amino acids for encapsulating active agents
US5578323A (en) 1992-06-15 1996-11-26 Emisphere Technologies, Inc. Proteinoid carriers and methods for preparation and use thereof
US5693338A (en) 1994-09-29 1997-12-02 Emisphere Technologies, Inc. Diketopiperazine-based delivery systems
US5714167A (en) 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
US5629020A (en) 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
US5443841A (en) 1992-06-15 1995-08-22 Emisphere Technologies, Inc. Proteinoid microspheres and methods for preparation and use thereof
US5541155A (en) 1994-04-22 1996-07-30 Emisphere Technologies, Inc. Acids and acid salts and their use in delivery systems
US6331318B1 (en) 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
US6099856A (en) 1992-06-15 2000-08-08 Emisphere Technologies, Inc. Active agent transport systems
US6221367B1 (en) 1992-06-15 2001-04-24 Emisphere Technologies, Inc. Active agent transport systems
WO1992020369A1 (en) * 1991-05-14 1992-11-26 Dana Farber Cancer Institute Use of hemoglobin in a method for the treatment of tumors with chemotherapeutic agents
US5627270A (en) 1991-12-13 1997-05-06 Trustees Of Princeton University Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
US5693769A (en) 1991-12-13 1997-12-02 Transcell Technologies, Inc. Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
US6916489B2 (en) 1992-06-15 2005-07-12 Emisphere Technologies, Inc. Active agent transport systems
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5401516A (en) 1992-12-21 1995-03-28 Emisphere Technologies, Inc. Modified hydrolyzed vegetable protein microspheres and methods for preparation and use thereof
US5958457A (en) 1993-04-22 1999-09-28 Emisphere Technologies, Inc. Compositions for the delivery of antigens
US20010003001A1 (en) 1993-04-22 2001-06-07 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5643957A (en) 1993-04-22 1997-07-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5709861A (en) 1993-04-22 1998-01-20 Emisphere Technologies, Inc. Compositions for the delivery of antigens
ES2244367T3 (es) 1993-04-22 2005-12-16 Emisphere Technologies, Inc. Composiciones para la administracion por via oral.
US6461643B2 (en) 1993-04-22 2002-10-08 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5908635A (en) 1994-08-05 1999-06-01 The United States Of America As Represented By The Department Of Health And Human Services Method for the liposomal delivery of nucleic acids
US6090958A (en) 1995-03-31 2000-07-18 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6001347A (en) 1995-03-31 1999-12-14 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
BR9604880A (pt) 1995-03-31 1998-05-19 Emisphere Tech Inc Composto composição forma de unidade de dosagem métodos para administração de um agente biologicamente ativo para preparar uma composição para administração de um agente ativo e para preparar um composto e composição farmacológica
US5989539A (en) 1995-03-31 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5866536A (en) * 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5965121A (en) 1995-03-31 1999-10-12 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US5601839A (en) 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
US5820881A (en) 1995-04-28 1998-10-13 Emisphere Technologies, Inc. Microspheres of diamide-dicarboxylic acids
US6051258A (en) 1995-06-07 2000-04-18 Emisphere Technologies, Inc. Proteinoid emulsions and methods for preparation and use thereof
US5756122A (en) 1995-06-07 1998-05-26 Georgetown University Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells
IL115199A (en) 1995-09-07 2005-05-17 Opperbas Holding Bv Composition comprising a polynucleic acid molecule in a liposome and method using said composition
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
WO1997030705A1 (en) * 1996-02-21 1997-08-28 Matrix Pharmaceutical, Inc. Use of cell membrane permeants in the treatment of cellular proliferative diseases
AU2595697A (en) 1996-03-29 1997-10-22 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
AU2911197A (en) 1996-05-24 1998-01-05 Imperial College Of Science, Technology And Medicine Polycationic sterol derivatives as transfection agents
US6313088B1 (en) 1997-02-07 2001-11-06 Emisphere Technologies, Inc. 8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents
US5990166A (en) 1997-02-07 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5939381A (en) 1997-02-07 1999-08-17 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6060513A (en) 1997-02-07 2000-05-09 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5876710A (en) 1997-02-07 1999-03-02 Emisphere Technologies Inc. Compounds and compositions for delivering active agents
US6051561A (en) 1997-02-07 2000-04-18 Emisphere Technologies Inc. Compounds and compositions for delivering active agents
US5879681A (en) 1997-02-07 1999-03-09 Emisphere Technolgies Inc. Compounds and compositions for delivering active agents
US5776888A (en) 1997-02-07 1998-07-07 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5804688A (en) 1997-02-07 1998-09-08 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6358504B1 (en) 1997-02-07 2002-03-19 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6126965A (en) 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
US20030229040A1 (en) 1997-03-21 2003-12-11 Georgetown University Cationic liposomal delivery system and therapeutic use thereof
US5863944A (en) 1997-04-30 1999-01-26 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
WO1998051278A2 (en) 1997-05-14 1998-11-19 Inex Pharmaceuticals Corporation High efficiency encapsulation of charged therapeutic agents in lipid vesicles
US6110492A (en) * 1997-05-28 2000-08-29 Jenner Biotherapies, Inc. Immunogenic compositions
WO1999001579A1 (en) 1997-07-01 1999-01-14 Isis Pharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
US20030073640A1 (en) 1997-07-23 2003-04-17 Ribozyme Pharmaceuticals, Inc. Novel compositions for the delivery of negatively charged molecules
JP2001510808A (ja) 1997-07-24 2001-08-07 イネックス ファーマシューティカルズ コーポレイション 核酸触媒の供給のためのリポソーム組成物
AU9016998A (en) * 1997-08-08 1999-03-01 Newbiotics, Inc. Methods and compositions for overcoming resistance to biologic and chemotherapy
US6225118B1 (en) 1997-10-01 2001-05-01 Biocure Limited Multicellular in vitro assay of angiogenesis
US7229841B2 (en) 2001-04-30 2007-06-12 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
JPH11246439A (ja) 1998-03-02 1999-09-14 Hisamitsu Pharmaceut Co Inc 経粘膜用吸収促進剤
NZ509238A (en) 1998-07-27 2003-07-25 Emisphere Tech Inc Pulmonary delivery of active agents the carrier containing acylated or sulfonated amino acids
US7648695B2 (en) 1998-08-06 2010-01-19 Provectus Pharmatech, Inc. Medicaments for chemotherapeutic treatment of disease
US6991798B1 (en) 1998-08-07 2006-01-31 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
IL140930A0 (en) 1998-08-07 2002-02-10 Emisphere Tech Inc Compounds and compositions for delivering active agents
EP1131344B1 (en) 1998-11-19 2005-08-03 ELAN CORPORATION, Plc Retro-inversion peptides that target gastro-intestinal tract transport receptors and use thereof
JP2002534363A (ja) 1999-01-08 2002-10-15 エミスフェアー・テクノロジーズ・インク ポリマー性デリバリー剤及びデリバリー剤化合物
US7084279B1 (en) 1999-02-11 2006-08-01 Emisphere Technologies Inc. Oxadiazole compounds and compositions for delivering active agents
CA2362550C (en) 1999-02-22 2010-05-11 Georgetown University Antibody fragment-targeted immunoliposomes for systemic gene delivery
WO2000050386A1 (en) 1999-02-26 2000-08-31 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6537585B1 (en) * 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
NZ534409A (en) 1999-04-05 2006-03-31 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US7112337B2 (en) 1999-04-23 2006-09-26 Alza Corporation Liposome composition for delivery of nucleic acid
US6780846B1 (en) 1999-09-27 2004-08-24 Elan Corporation, Plc Membrane translocating peptide drug delivery system
US20030181367A1 (en) 1999-09-27 2003-09-25 O'mahony Daniel Conjugates of membrane translocating agents and pharmaceutically active agents
US6200599B1 (en) 1999-10-07 2001-03-13 The Regents Of The University Of California Ortho ester lipids
US6511676B1 (en) 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
US7279597B1 (en) 1999-11-05 2007-10-09 Emisphere Technologies, Inc. Phenyl amine carboxylic acid compounds and compositions for delivering active agents
US7129274B1 (en) 1999-11-05 2006-10-31 Emisphere Technologies Inc. Phenoxy carboxylic acid compounds and compositions for delivering active agents
US20050037086A1 (en) 1999-11-19 2005-02-17 Zycos Inc., A Delaware Corporation Continuous-flow method for preparing microparticles
EP1237872B1 (en) 1999-12-16 2008-02-27 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US7151191B2 (en) 2000-01-13 2006-12-19 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
CA2402613A1 (en) 2000-03-29 2001-10-04 Igor Gonda Cationic liposomes
US20030072794A1 (en) 2000-06-09 2003-04-17 Teni Boulikas Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes
UA80248C2 (en) 2000-06-29 2007-09-10 Compounds and compositions for delivering active agents
JP4707931B2 (ja) 2000-08-18 2011-06-22 エミスフェアー・テクノロジーズ・インク 活性剤デリバリー用化合物および組成物
AU2001284985A1 (en) 2000-08-18 2002-03-04 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
BR0114799A (pt) 2000-09-06 2003-12-30 Emisphere Tech Inc Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
DE60134245D1 (de) 2000-09-06 2008-07-10 Emisphere Tech Inc (5-(2-hydroxy-4-chlorbenzoyl)valeriansäure und deren salze, und zusammensetzungen zur zuführung von wirkstoffen, die diese verbindungen enthalten
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
KR100872437B1 (ko) 2000-12-01 2008-12-05 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
WO2002069937A1 (en) 2001-03-01 2002-09-12 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
WO2002076427A2 (en) 2001-03-26 2002-10-03 Thomas Jefferson University Ph sensitive liposomal drug delivery
EP1385479A4 (en) 2001-03-26 2006-12-06 Alza Corp LIPOSOMIC COMPOSITION FOR IMPROVED INTRA-CELLULAR RELEASE OF A THERAPEUTIC AGENT
US20030026831A1 (en) 2001-04-20 2003-02-06 Aparna Lakkaraju Anionic liposomes for delivery of bioactive agents
AU2002256398A2 (en) 2001-04-30 2002-11-11 Targeted Genetics Corporation Lipid-comprising drug delivery complexes and methods for their production
EP1390383B1 (en) 2001-05-11 2012-02-29 Isis Pharmaceuticals, Inc. Antisense permeation enhancers
WO2003003999A2 (en) 2001-07-02 2003-01-16 Elan Corporation, Plc. Delivery of a bioactive material
WO2003004517A2 (en) 2001-07-02 2003-01-16 Elan Corporation, Plc Peyers's patch and/or m-celle targeting ligands
BR0103887C1 (pt) * 2001-07-17 2005-11-08 Univ Minas Gerais Composições imunogênicas contendo microesferas biodegradáveis encapsulando antìgenos, vetores gênicos e adjuvantes
AU2002323151A1 (en) 2001-08-13 2003-03-03 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
DE10152145A1 (de) 2001-10-19 2003-05-22 Novosom Ag Stabilisierung von Liposomen und Emulsionen
JP4602668B2 (ja) 2001-11-13 2010-12-22 エミスフェアー・テクノロジーズ・インク 活性剤を送達するためのフェノキシアミン化合物および組成物
US20030118657A1 (en) 2001-12-04 2003-06-26 West Jennifer L. Treatment of disease states characterized by excessive or inappropriate angiogenesis
WO2003057190A1 (en) 2001-12-31 2003-07-17 Elan Pharmaceuticals, Inc. Efficient nucleic acid encapsulation into medium sized liposomes
WO2003059322A1 (en) 2002-01-09 2003-07-24 Elan Pharmaceuticals, Inc. Efficient nucleic acid encapsulation into medium sized liposomes
CA2471144C (en) 2002-01-09 2011-06-07 Emisphere Technologies, Inc. Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoate
DE10207177A1 (de) 2002-02-19 2003-09-04 Novosom Ag Fakultativ kationische Lipide
US7037520B2 (en) 2002-03-22 2006-05-02 Baylor College Of Medicine Reversible masking of liposomal complexes for targeted delivery
WO2003083443A2 (en) 2002-03-29 2003-10-09 University Of Florida Lipid mediated screening of drug candidates for identification of active compounds
WO2003099298A1 (en) 2002-05-24 2003-12-04 Max-Planck Gesellschaft zur Förderung der Wissenschaften e.V. Rna interference mediating small rna molecules
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
US20070071677A1 (en) * 2003-03-10 2007-03-29 Park Yoon J Non-toxic membrane-translocating peptides
WO2004081196A2 (en) * 2003-03-11 2004-09-23 Qlt Usa Inc. Formulations for cell- schedule dependent anticancer agents
US8084599B2 (en) 2004-03-15 2011-12-27 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
RU2006136790A (ru) 2004-04-16 2008-05-27 Эмисфире Текнолоджис, Инк. (Us) 8-(2-гидроксифенокси)октилдиетаноламин и его соли для доставки активных агентов
ES2729825T3 (es) * 2004-05-06 2019-11-06 Emisphere Tech Inc Formas poliméricas cristalinas de N-[8-(2-hidroxibenzoil)amino]caprilato monosódico
CA2566161C (en) * 2004-05-14 2013-10-01 Emisphere Technologies, Inc. Aryl ketone compounds and compositions for delivering active agents
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
US7297786B2 (en) 2004-07-09 2007-11-20 University Of Iowa Research Foundation RNA interference in respiratory epitheial cells
US9345725B2 (en) * 2004-12-29 2016-05-24 Emisphere Technologies, Inc. Pharmaceutical formulations of gallium salts
US7820628B2 (en) 2005-02-22 2010-10-26 University Of Massachusetts Medical School Tumor lesion regression and conversion in situ into autologous tumor vaccines by compositions that result in anti-Gal antibody binding
US20070049557A1 (en) 2005-08-24 2007-03-01 Hashim Ahmed Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
CN101627011A (zh) 2005-09-19 2010-01-13 爱密斯菲尔科技公司 N-(5-氯水杨酰基)-8-氨基辛酸的二钠盐的晶形
WO2007069068A2 (en) * 2005-12-16 2007-06-21 Diatos Cell penetrating peptide conjugates for delivering nucleic acids into cells
WO2007085026A2 (en) 2006-01-20 2007-07-26 The Board Of Regents Of The University Of Texas System Compositions and methods for the direct therapy of tumors
CN101668512A (zh) * 2007-01-31 2010-03-10 新泽西鲁特格斯州立大学 皮肤中活性物质的控制释放
US8168757B2 (en) * 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
US20090275654A1 (en) 2008-04-30 2009-11-05 Genta Incorporated Pharmaceutical Gallium Compositions and Methods
EP2303280A2 (en) * 2008-05-30 2011-04-06 Novelix Pharmaceuticals, Inc. Compositions and methods for treatment of inflammation and hyperkeratotic lesions
BRPI1005919B1 (pt) * 2009-02-27 2021-06-22 Toray Industries, Inc Composição imunogênica
WO2011084061A1 (en) * 2010-01-08 2011-07-14 Universitair Medisch Centrum St. Radboud Cpp (cell penetrating peptide) and its uses
CN101928234B (zh) 2010-01-15 2012-12-12 北京欧凯纳斯科技有限公司 6/7-（杂）芳基-n-羟基己/庚酰胺化合物及其制备方法
CA2792754C (en) * 2010-03-12 2019-11-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services .beta.-mannosylceramide and stimulation of nkt cell anti-tumor immunity
ES2829819T3 (es) 2010-08-26 2021-06-02 Toray Industries Composición inmunogénica
EP2877159B8 (en) 2012-07-27 2018-02-14 Izumi Technology, LLC. Efflux inhibitor compositions and methods of treatment using the same
PT2897620T (pt) 2012-09-21 2020-09-03 Intensity Therapeutics Inc Método de tratamento de cancro

Also Published As

Publication number Publication date
US10888618B2 (en) 2021-01-12
RU2657749C2 (ru) 2018-06-15
US9636406B2 (en) 2017-05-02
JP2018123137A (ja) 2018-08-09
IL237791B (en) 2020-10-29
WO2014046983A9 (en) 2015-04-30
US20140248211A1 (en) 2014-09-04
SMT202000452T1 (it) 2020-09-10
EP2897620A4 (en) 2016-04-27
DK2897620T3 (da) 2020-08-17
CN104884065A (zh) 2015-09-02
BR112015006176B1 (pt) 2023-04-18
US12496345B2 (en) 2025-12-16
CY1123258T1 (el) 2021-12-31
AU2013318338B2 (en) 2017-05-25
US20210077627A1 (en) 2021-03-18
WO2014046983A1 (en) 2014-03-27
KR101839864B1 (ko) 2018-03-20
AU2013318338A1 (en) 2015-03-26
US20160166697A1 (en) 2016-06-16
AU2017202970A1 (en) 2017-05-25
KR20150064097A (ko) 2015-06-10
SG10202011046RA (en) 2020-12-30
US20260069697A1 (en) 2026-03-12
RU2015114767A (ru) 2016-11-20
SG11201501850VA (en) 2015-04-29
BR112015006176A8 (pt) 2018-06-26
MX2015003643A (es) 2016-04-06
EP2897620B1 (en) 2020-07-22
US20170165369A1 (en) 2017-06-15
PL2897620T3 (pl) 2020-11-02
JP6374388B2 (ja) 2018-08-15
PT2897620T (pt) 2020-09-03
CL2015000699A1 (es) 2015-11-27
US9351997B2 (en) 2016-05-31
CA2884707C (en) 2019-03-19
CN104884065B (zh) 2019-01-01
US20230338251A1 (en) 2023-10-26
IL237791A0 (en) 2015-05-31
EP2897620A1 (en) 2015-07-29
CA2884707A1 (en) 2014-03-27
ES2813340T3 (es) 2021-03-23
AU2017202970B2 (en) 2018-10-04
JP2015533809A (ja) 2015-11-26

Similar Documents

Publication Publication Date Title
CY1123258T1 (el) Μεθοδος θεραπειας για τον καρκινο
NZ700759A (en) Combination therapy for treating cancer
MY186977A (en) Tetrasubstituted alkene compounds and their use
PH12012502399A1 (en) Combination therapy methods for treating proliferative diseases
MX344355B (es) Uso de inhibidores de erbb3 en el tratamiento de canceres de mama triple negativos y de tipo basal.
SG10201902664RA (en) Combination therapy for treating cancer
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
HK1211832A1 (zh) 用於癌症療法的抗高血壓藥物的新穎配方及用法
EP3208615A3 (en) Uses of labeled hsp90 inhibitors
NZ719049A (en) Cancer treatment with combination of plinabulin and taxane
MY189663A (en) Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
NZ712691A (en) C. novyi for the treatment of solid tumors in humans
MX2017006076A (es) Dianhidrogalactitol junto con radiacion, para tratar carcinoma de pulmón de celulas no pequeñas y glioblastoma multiforme.
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2020001727A (es) Terapia de combinacion.
HK1250626A1 (zh) 借助塞里班土单抗的组合治疗
MX2015015434A (es) Corroles dirigidas para toxicidad tumoral y rm.
WO2013052158A3 (en) Targeted nanovectors and their use for treatment of brain tumors
MY197664A (en) Immunity enhancing agent for cancer by allergin-1 antagonist
MX2018006776A (es) Usos de pirimido-piridazinonas para tratar el cancer.
WO2014160967A3 (en) C. novyi for the treatment of solid tumors in non-human animals
TN2014000418A1 (en) Methods for treating cancer using pi3k inhibitor and mek inhibitor
NZ742470A (en) Combination therapy for cancer
PH12014502464A1 (en) Veliparib in combination with whole brain radiation therapy for the treatment of brain metastases
IN2013MU00957A (es)

Legal Events

Date Code Title Description
FG Grant or registration